Načítá se...

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

Treatment for chronic myeloid leukemia (CML) has improved substantially in the last 20 years, especially since the introduction of oral BCR-ABL inhibitors a decade ago. However, for patients to reap the benefits of BCR-ABL inhibitors, they must likely be on therapy for the remainder of their lives....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Lymphoma Myeloma Leuk
Hlavní autoři: Jabbour, Elias, Saglio, Giuseppe, Radich, Jerald, Kantarjian, Hagop
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4428159/
https://ncbi.nlm.nih.gov/pubmed/22633166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.04.002
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!